DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Most psych meds combine safely with GLP‑1. Lithium needs monitoring. Antipsychotic-induced weight gain reverses on GLP‑1 (major emerging use case). Lancet Psychiatry 2026 Swedish cohort data.
Most psychiatric meds + GLP-1 = safe with monitoring
Lancet Psychiatry 2026 Swedish cohort: 12,000 GLP-1 patients with depression showed slight improvement in mood vs matched controls. Lithium needs careful monitoring due to narrow therapeutic index. Atypical antipsychotic weight gain reverses substantially on GLP-1 — major emerging psychiatric use case.
sertraline, escitalopram, fluoxetine, citalopram, paroxetine
Interaction: Slight absorption delay, no clinically significant effect
Guidance: Continue without dose change. Monitor mood normally during titration — early GI side effects can be mistaken for SSRI worsening.
venlafaxine, duloxetine, desvenlafaxine
Interaction: Absorption delay; some patients report intensified nausea early
Guidance: Continue. If nausea worsens substantially, consider switching SNRI to morning dosing or adding anti-emetic during titration weeks.
olanzapine, quetiapine, risperidone, clozapine, paliperidone
Interaction: Known to cause significant weight gain (5-30 lb) — GLP-1 can REVERSE this
Guidance: Strong potential benefit. GLP-1 can offset antipsychotic-induced metabolic syndrome. Coordinate with psychiatrist + endocrinologist. Major emerging use case.
lithium carbonate, lithium citrate
Interaction: Narrow therapeutic index — dehydration from GLP-1 GI side effects can cause toxicity
Guidance: Monitor lithium levels weekly first month, then monthly. Aggressive hydration during titration. Slow GLP-1 titration. Some psychiatrists pause GLP-1 during lithium dose changes.
phenelzine, tranylcypromine, isocarboxazid, selegiline
Interaction: No direct interaction but dietary restrictions overlap with GLP-1 appetite suppression challenges
Guidance: Maintain MAOI dietary restrictions (tyramine-low). GLP-1 may reduce intake further — ensure adequate nutrition. Psychiatric oversight critical.
valproate, lamotrigine, carbamazepine
Interaction: Valproate weight gain offset by GLP-1; lamotrigine no significant interaction
Guidance: Continue. Valproate-induced weight gain is well-documented; GLP-1 can offset 5-15 lb of this. Monitor mood stability during titration.
alprazolam, lorazepam, diazepam, clonazepam
Interaction: No clinically significant interaction
Guidance: Continue without modification. GLP-1 may improve sleep quality independent of benzo use.
amphetamine, methylphenidate, lisdexamfetamine
Interaction: IR formulations spread absorption — act more like XR. See /adhd page
Guidance: Often beneficial. Smoother stimulant effect + appetite control complement. See /adhd for detail.
Lancet Psychiatry 2026 Swedish cohort (N=12,000 patients with depression starting GLP-1): no increase in depression symptoms; actually slight improvement vs matched non-GLP-1 cohort. Weight loss + metabolic improvement + reduced food shame all contribute. Continue SSRI/SNRI normally.
Yes — substantially. Patients on olanzapine, clozapine, risperidone often gain 10-30 lb in first year. GLP-1 can offset this entirely in many cases. Strongest emerging psychiatric use case. Coordinate prescribing across psychiatry + obesity medicine.
Lithium has narrow therapeutic index (0.6-1.2 mEq/L). GLP-1 nausea/vomiting → dehydration → reduced renal clearance → lithium toxicity. Most psychiatrists allow combination with weekly level monitoring first month, then monthly. Aggressive hydration mandatory.
Yes. Eating disorder history is a contraindication for some products. Bipolar history requires careful management of GLP-1's effect on appetite signaling. Active substance use disorder requires coordination. Disclose for safety, not stigma.
FDA reviewing post-market signal data. Most cohort studies show NO increase in suicidal ideation. Some patients report improved mood from weight loss + reduced food noise. If you have history of self-harm, screen baseline + monitor weekly first 3 months.
Coordinate prescribing. Psychiatrist + obesity medicine specialist + primary care should all know about all medications. Disclose eating disorder + substance use + suicidal ideation history before GLP-1. NAMI helpline 1-800-950-NAMI for psychiatric resources.